Mundo Sano

What Mundo Sano does

Mundo Sano is a private family foundation established in Argentina in 1993 and registered in Barcelona as Fundación Mundo Sano (CIF G-61911335). It is part of the Insud Pharma group and operates as a nonprofit dedicated to reducing the impact of neglected tropical diseases, including Chagas disease, geohelminthiasis, strongyloidiasis, and mosquito-borne illnesses. The foundation operates from a Buenos Aires regional headquarters (Paraguay 1535), a Madrid regional headquarters (Recaredo 3), its registered Barcelona office (Gran Vía Carlos III 98), and four Argentine field offices in Añatuya, Tartagal, Pampa del Indio/Clorinda, and Puerto Iguazú, coordinating programs across Latin America, Africa, Europe and the United States.

The foundation's core technical platform is translational research applied to neglected diseases, combining field epidemiology with proprietary diagnostic innovation. Its flagship technology is the ChagasLAMP Loop-mediated Isothermal Amplification molecular diagnostic for congenital Chagas disease, paired with a 3D-printer-based point-of-care DNA extraction method. Supporting capabilities include a Data Analysis Laboratory, geospatial epidemiology tools (delivered through the Diploma in Health Geomatics), pooled-testing methodology used in its COVID-19 surveillance model, and a Sentinel Laboratory Network for Chagas in Europe. The foundation also co-formulates pharmaceuticals (ivermectin+albendazole) and runs vector-control programs.

Mundo Sano's business model is grant and foundation-funded rather than commercial. Services are delivered free of charge to vulnerable beneficiaries through public-private partnerships with government health ministries in Argentina, Bolivia, Paraguay, Ethiopia and Guatemala. Revenue streams are institutional grants and partnerships, with explicit reliance on its Insud Pharma parent for financial backing. Distribution is direct through public health system integration and on-the-ground field operations, supplemented by international organization partnerships with PAHO (since 2016), WHO (since 2017), DNDi, ISGlobal, IDB and GHIT Fund. Go-to-market is community-led via field offices, local health agents and global policy engagement, with marketing centered on scientific publications, conferences, and bilingual digital communications rather than commercial promotion.

Name

Mundo Sano

Legal name

Fundación Mundo Sano

Website

https://mundosano.org

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

51–100 employees

Short description

Mundo Sano is a nonprofit family foundation (part of the Insud Pharma group) that develops diagnostics, treatment programs, and field operations to combat neglected tropical diseases such as Chagas, strongyloidiasis, and geohelminthiasis among vulnerable populations across Latin America, Africa, and Europe.

Ownership category

akta.pro rank

Product category

Public Health Foundation

NAICS

Religious, Grantmaking, Civic, Professional, and Similar Organizations (813), Grantmaking and Giving Services (81321)

SIC

Services-Health Services (8000), Services-Membership Organizations (8600)

akta.pro primary industry

Disease-Specific Global Programs (HIV/TB/Malaria/NTDs) (HLAJAKAF)

akta.pro secondary industries

Global Health Systems Strengthening (BPAGABAD), Health Systems Strengthening & Global Health Technical Assistance (BPADAEAH), Maternal, Newborn, Child & Adolescent Health (MNCAH) Partnerships (HLAJAOAG), One Health & Zoonotic Disease Partnerships (Human–Animal–Environment) (HLAJAOAJ)

Keywords

• Neglected tropical diseases
• Public health foundation
• Disease diagnostics research
• Chagas disease programs
• Community health interventions

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Foundation / Grant Funding: As a family foundation established in 1993, Mundo Sano operates as part of Insud Pharma group. Revenue is derived from institutional funding, grants, and partnerships rather than commercial product sales. The foundation develops management models that are replicable, scalable, and transferable through public-private alliances.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Mundo Sano is a nonprofit family foundation established in 1993 in Argentina that develops replicable, scalable, and transferable disease management models for neglected tropical diseases. The foundation combines direct field operations in endemic communities with scientific research to address Chagas disease, geohelminthiasis, strongyloidiasis, and mosquito-borne diseases. It works through public-private partnerships with governments, international organizations, and research institutions to deliver diagnostic innovation, professional training, and community-based intervention programs.

Product overview

Mundo Sano is a family foundation established in 1993 that works to reduce the impact of neglected health issues. The organization offers a portfolio of research projects, scientific publications, training programs, and diagnostic technologies focused on neglected tropical diseases. Key offerings include scientific knowledge sharing services (publications, events, data laboratories), professional healthcare training programs (including Diploma in Health Geomatics), and various disease-specific projects addressing Chagas disease, geohelminths, and mosquito-borne diseases. The organization develops innovative diagnostic tools such as the ChagasLAMP molecular diagnostic technique and 3D printer-based DNA extraction methods. Programs include SAFEStart+ for maternal-child health, ivermectin access expansion initiatives, and the Atendiendo Chagas online community platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Diploma in Health Geomatics
• Professional Healthcare Training
• SAFEStart+
• ChagasLAMP
• 3D Printer-Based DNA Extraction
• Strongyloidiasis Rapid Test
• COVID-19 Comprehensive Response Model
• Atendiendo Chagas Platform

Quantifiable outcome

• COVID-19 incidence rate reduced to 216 per 10,000 in project area vs 287 regional average
• +3 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

17 partnerships are on record, tiered core and minor.

• Organización Mundial de la Salud (WHO/OMS)coreStrategic or Co-development Partner · 1 April 2017Alliance established in 2017 following participation in Global Partners Meeting on Neglected Tropical Diseases. Partnership focuses on strengthening access to diagnosis and treatment of Chagas disease.
• Organización Panamericana de la Salud (PAHO/OPS)coreStrategic or Co-development Partner · 1 January 2016Official relations since 2016. Collaboration includes ETMI Plus initiative for elimination of mother-to-child disease transmission (HIV, syphilis, hepatitis B, Chagas). PAHO facilitates technical exchange, regional guidelines, and supports analysis and dissemination of learnings.
• Uniting to Combat NTDscoreStrategic or Co-development PartnerOnly Latin American organization member of this coalition promoted by Bill & Melinda Gates Foundation, created to reduce impact of 10 neglected tropical diseases.
• Coalición Global de ChagascoreStrategic or Co-development PartnerFounding partner along with DNDi, Sabin Vaccine Institute, ISGlobal, and CEADES. Coalition works to advance Chagas disease control and treatment.
• Drugs for Neglected Diseases Initiative (DNDi)coreStrategic or Co-development PartnerAlliance renewed in 2022. Collaboration on drug development and access for neglected diseases including Chagas.
• Children Without WormsminorStrategic or Co-development PartnerMember of coalition working to increase efforts in addressing geohelminthiasis control.
• Iniciativa Iberoamericana Ningún Bebé con ChagascoreStrategic or Co-development PartnerTechnical Unit since 2021. Eight countries participate through SEGIB (Secretaría General Iberoamericana). Focus on eliminating congenital Chagas transmission.
• Universidad de Harvard - T.H. Chan School of Public HealthminorStrategic or Co-development PartnerFramework cooperation agreement for academic collaboration in public health research.
• Instituto Gulich / Universidad Nacional de CórdobaminorStrategic or Co-development PartnerCollaboration on Diploma in Health Geomatics - first program of its kind in Argentina. Virtual campus collaboration with IDB and Government of Japan support.
• Hospital Universitario Ramón y CajalminorImplementation/ SI/ Consulting PartnerCooperation agreement for Chagas disease research and training.
• Hospital Vall d'HebronminorImplementation/ SI/ Consulting PartnerMedical research collaboration in Barcelona.
• Universidad de Buenos Aires (UBA)minorStrategic or Co-development PartnerAcademic collaboration including laboratory work for COVID-19 project at Faculty of Pharmacy and Biochemistry.
• Universidad Bahir Dar (Ethiopia)minorStrategic or Co-development PartnerAcademic partnership for research on geohelminths and neglected tropical diseases.
• Ministerio de Salud de ArgentinacoreImplementation/ SI/ Consulting PartnerNational health ministry partnerships for program implementation and disease surveillance.
• Ministerio de Salud de BoliviacoreImplementation/ SI/ Consulting PartnerETMI Plus implementation and congenital Chagas elimination programs.
• Ministerio de Salud de EtiopíacoreImplementation/ SI/ Consulting PartnerStrongyloidiasis control and integration into national neglected tropical disease plans.
• ISGlobal (Instituto de Salud Global de Barcelona)coreStrategic or Co-development PartnerCo-founder of Chagas Coalition and partner in ChagasLAMP project for diagnostic innovation.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• The END Fund: Private-philanthropy vehicle dedicated to ending NTDs, with comparable grantmaking, government partnerships, and field-delivery focus. Direct comparator for foundation-driven NTD program delivery.
• Sabin Vaccine Institute: Washington, DC-based NTD advocacy and vaccine organization; fellow co-founder of the Global Chagas Coalition. Comparable as an NGO driving NTD policy, R&D funding, and global partnerships.
• ISGlobal (Barcelona Institute for Global Health): Barcelona-based global health research institute co-founder of the Chagas Coalition and partner in ChagasLAMP. Highly comparable as a Spanish-headquartered research-to-policy NTD player with overlapping leadership networks.
• Drugs for Neglected Diseases initiative (DNDi): Product Development Partnership (PDP) focused on new treatments for neglected diseases including Chagas. Direct counterpart for Mundo Sano on the Chagas Coalition, with a renewed 2022 alliance and overlapping Chagas elimination agenda.
• Task Force for Global Health (NTD Center): Home of the NTD Support Center led by Advisory Board member Dr. Patrick Lammie. Overlapping mandate on NTD program delivery, surveillance, and donor coordination.

Broad incumbents

• PATH: Large global health nonprofit with diagnostic and NTD programs across multiple diseases; broader portfolio than Mundo Sano but operates with overlapping ministry-of-health and field-program delivery model.
• Bill & Melinda Gates Foundation (Global Health): Founding funder of 'Uniting to Combat NTDs' (of which Mundo Sano is a member). Operates at vastly larger scale but directly shapes the NTD agenda and grant ecosystem that Mundo Sano depends on.
• Clinton Health Access Initiative (CHAI): Operates government engagement and technical assistance models in LMICs similar to Mundo Sano's field offices, with strong donor and ministry relationships across Latin America and Africa.

Emerging players

• Malaria Consortium: Specializes in malaria and NTD prevention at the community level. Comparable operational model (community-led programs, ministry partnerships) though focused on a different disease cluster.

Others

• Fundación Mundo Sano Spain (Insud Pharma-related health foundations): Parent group Insud Pharma is the structural anchor for Mundo Sano; comparable foundation arms inside large pharma groups (e.g., Novartis Foundation, GSK Foundation) share the public-private partnership and NTD programming model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MundoSano
• Facebookfacebook.com/FundacionMundoSano

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mundo Sano